Wall Street analyst estimates for Context Therapeutics Inc. (CNTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 0.91 |
| EV / EBITDA | 0.23 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $2.4M | $1.6M | $3.8M | $7.1M | $17.8M | $22.7M | $31.9M |
| Selling, General & Admin | $3.0M | $930667 | $3.6M | $7.8M | $7.3M | $7.2M | $7.8M |
| Operating Expenses | $5.4M | $2.6M | $10.5M | $15.4M | $25.1M | $29.9M | $39.7M |
| Operating Income | -$5.4M | -$2.6M | -$10.5M | -$15.4M | -$25.1M | -$29.9M | -$39.7M |
| EBITDA | -$5.4M | -$2.6M | -$10.5M | -$14.9M | -$24.0M | -$26.7M | -$36.1M |
| Interest Expense | $1.1M | $661224 | $64240 | $547268 | 0 | 0 | 0 |
| Pre-tax Income | -$6.4M | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$6.4M | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| EPS | $-0.68 | $0.10 | $-3.69 | $-0.93 | $-1.50 | $-0.46 | $-0.38 |
| EPS (Diluted) | $-0.68 | $0.10 | $-3.69 | $-0.93 | $-1.50 | $-0.46 | $-0.38 |
| Shares Outstanding (Diluted) | $11.0M | $11.0M | $2.8M | $16.0M | $16.0M | $58.4M | $95.2M |
Price
| Price | $0.38 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLNN · CNTB · IFRX · IMA · KLRS · MGNX · ORMP
Explore sector: Healthcare · Biotechnology
More sections of CNTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks